Research Analysts Offer Predictions for DNLI FY2029 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Analysts at B. Riley issued their FY2029 EPS estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the company will post earnings of $0.87 per share for the year. B. Riley currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

A number of other research firms have also recently weighed in on DNLI. Morgan Stanley began coverage on Denali Therapeutics in a research report on Friday. They set an “overweight” rating and a $33.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. Oppenheimer lowered their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright lifted their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a report on Friday, February 28th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $37.27.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $16.69 on Thursday. Denali Therapeutics has a fifty-two week low of $14.01 and a fifty-two week high of $33.33. The firm has a 50-day simple moving average of $20.88 and a 200-day simple moving average of $24.35. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -6.05 and a beta of 1.43.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNLI. FMR LLC increased its stake in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Denali Therapeutics by 63.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after purchasing an additional 1,451,770 shares during the last quarter. Norges Bank purchased a new position in Denali Therapeutics in the 4th quarter valued at about $21,717,000. Wellington Management Group LLP lifted its holdings in Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after purchasing an additional 843,996 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the transaction, the chief executive officer now owns 260,721 shares of the company’s stock, valued at $5,271,778.62. The trade was a 10.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,940 shares of company stock worth $973,442 in the last quarter. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.